Risk adjusted net present value: What is the current valuation of Solid Biosciences’s SGT-003?
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.
What's Your Reaction?
